India Coronavirus Dispatch: UP, Bihar worst in Covid reporting, finds study

Daily positivity rate at 11.61%, private hospitals struggle to access remdesivir, and how much should you worry about air conditioning-news on how India is dealing with the pandemic

Interview

Itolizumab a game-changer in trying to reduce mortality, not for Covid: Biocon said it was launching itolizumab, for emergency use to treat cytokine release syndrome in moderate to severe cases of acute respiratory distress syndrome due to Covid-19. Itolizumab has been used to treat psoriasis. The drug regulates the immune response in order to prevent a cytokine storm -- when excessive or uncontrolled levels of cytokines are released, activating more immune cells. This results in hyperinflammation, and causes sepsis or organ failure, which can all be fatal. Read this interview with Hemant Thacker, the first Mumbai